Fredag 27 Februari | 08:10:39 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2027-02-11 08:00 Bokslutskommuniké 2026
2026-11-05 08:00 Kvartalsrapport 2026-Q3
2026-08-13 08:00 Kvartalsrapport 2026-Q2
2026-05-15 N/A X-dag ordinarie utdelning ACARIX 0.00 SEK
2026-05-13 N/A Årsstämma
2026-05-07 08:00 Kvartalsrapport 2026-Q1
2026-02-12 - Bokslutskommuniké 2025
2025-11-06 - Kvartalsrapport 2025-Q3
2025-10-27 - Extra Bolagsstämma 2025
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-16 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2025-05-15 - Årsstämma
2025-05-12 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2024-05-14 - Årsstämma
2024-05-14 - Kvartalsrapport 2024-Q1
2024-02-21 - Extra Bolagsstämma 2024
2024-02-15 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-09-28 - Extra Bolagsstämma 2023
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2023-05-11 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-12-09 - Extra Bolagsstämma 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2022-05-11 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-23 - Extra Bolagsstämma 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2021-05-11 - Årsstämma
2021-05-11 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-08-11 - Extra Bolagsstämma 2020
2020-05-15 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2020-05-14 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-08-16 - Extra Bolagsstämma 2019
2019-05-17 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-14 - Kvartalsrapport 2018-Q3
2018-08-21 - Kvartalsrapport 2018-Q2
2018-05-24 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2018-05-23 - Årsstämma
2018-05-23 - Kvartalsrapport 2018-Q1
2018-02-26 - Bokslutskommuniké 2017
2017-11-14 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-26 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2017-05-24 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-02-23 - Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Acarix är ett diagnostikbolag. Bolaget har utvecklat en teknologi som möjliggör identifiering av kranskärlssjukdomar. Bolagets produkt är ett icke-invasivt test som sätts med en lapp på patienten för att analysera ljud från hjärtat. Verksamheten bedrivs främst inom den nordiska marknaden. Bolaget grundades 2009 som en avknoppning från Coloplast. Huvudkontoret ligger i Malmö.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-02-12 08:00:00

Malmö, Sweden – Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its 2025 year-end financial results. “Last year was a year of meaningful commercial and operational progress for Acarix,” said the company’s leadership team in a joint statement. “We delivered sustained revenue growth, expanded system placements and utilization, and materially strengthened our financial discipline. With growing reimbursement support, lower operating costs, and continued momentum entering 2026, Acarix is building a stronger, more scalable foundation for long-term growth.”

“Our performance in the fourth quarter reflects a company increasingly aligned around execution,” said Aamir Mahmood, President & CEO of Acarix. “Fourth quarter revenue grew 26%, system deliveries increased 64%, and U.S. patch sales rose 73%, while operating costs were reduced by 23%, resulting in a 27% improvement in net loss. At the same time, key milestones such as new U.S. reimbursement coverage and EU MDR certification further strengthen our commercial position as we focus on driving utilization and recurring revenue.”

When speaking on the future of Acarix, Mahmood went on to say, “As we enter 2026, our focus is on converting reimbursement momentum and system placements into higher utilization and recurring revenue. With a strengthened balance sheet, a disciplined cost base, and expanding access in Europe and the U.S., we believe Acarix is well positioned to scale sustainably while advancing earlier, more confident cardiac care.”

Key Highlights

  • Q4 revenue increased 26% to SEK 2,141 thousand, supported by 87% growth in the U.S. market.
  • A total of 23 CADScor® Systems were delivered in Q4, representing a 64% increase compared to 2024.
  • Patch sales increased 2% year-over-year, including 73% growth in the U.S.
  • Operating costs declined 23% compared to 2024, contributing to a 27% improvement in net loss.

Fourth quarter 2025 compared to the same period in 2024

  • Total revenue amounted to SEK 2,141 thousand (1,700), an increase of 26%.
  • In the U.S., revenue amounted to SEK 1,792 thousand (962) and an increase by 87%.
  • A total of 23 CADScor Systems (14) were delivered, an increase of 64%. 4 systems were consigned and 19 sold in the U.S. market.
  • A total of 171 boxes of patches (167) were sold, reflecting a 2% increase (1 box consists of 20 patches).
  • In the U.S., patch sales amounted to 126 boxes (73), an increase of 73%.
  • Gross margin amounted to 83% (88%).
  • Operating costs amounted to SEK 13,728 thousand (17,812), a decrease of 23%.
  • Net loss was SEK –11,673 thousand (−16,020), an improvement of 27%.
  • Cash flow from operating activities was SEK -16,891 thousand (-16,638).
  • Earnings per share were SEK -0.01 (-0.01).

Full year 2025 compared to the same period in 2024

  • Total revenue amounted to SEK 7,361 thousand (6,202), an increase of 19%.
  • In the U.S., revenue amounted to SEK 4,388 thousand (3,620), an increase of 21%.
  • A total of 101 CADScor Systems (62) were delivered, an increase of 63%.
  • In the U.S., 83 CADScor Systems (60) were delivered, an increase of 38%.
  • A total of 679 boxes of patches (587) were sold, an increase of 16%.
  • In the U.S., 380 boxes of patches (257) were sold, an increase of 48%.
  • Gross margin amounted to 85% (90%).
  • Operating costs amounted to SEK 54,250 thousand (71,968), an improvement of 25%.
  • Net loss amounted to SEK -48,091 thousand (-66,187), an improvement of 27%.
  • Cash flow from operating activities was SEK -48,383 thousand (-63,325).
  • Earnings per share amounted to SEK –0.04 (–0.07).
  • Average number of shares amounted to 1,126,768 (920,813).

The 2025 annual report will be available on the company’s website on April 15, 2026.
The 2026 Annual General Meeting will take place on May 13, 2026.

Webcast presentation of the Q4 year-end report will be available on: https://acarix.com/investor-presentations/

Link to the Acarix financial reports:
https://acarix.com/financial-reports-and-calendar/